Oncotarget

Research Papers:

CD19+CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer

Weiwei Wang, Xiangliang Yuan, Hui Chen, Guohua Xie, Yanhui Ma, Yingxia Zheng, Yunlan Zhou and Lisong Shen _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:33486-33499. https://doi.org/10.18632/oncotarget.5588

Metrics: PDF 3071 views  |   HTML 3743 views  |   ?  


Abstract

Weiwei Wang1, Xiangliang Yuan1, Hui Chen1, Guohua Xie1, Yanhui Ma1, Yingxia Zheng1, Yunlan Zhou1 and Lisong Shen1

1 Department of Clinical Laboratory, Xinhua Hospital, affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Correspondence to:

Lisong Shen, email:

Keywords: gastric cancer, regulatory B cells, IL-10, TGF-β, regulatory T cells, immune escape

Received: January 30, 2015 Accepted: August 23, 2015 Published: September 10, 2015

Abstract

Regulatory B cells (Bregs) play a critical role in inflammation and autoimmune disease. We characterized the role of Bregs in the progression of gastric cancer. We detected an increase in Bregs producing IL-10 both in peripheral blood mononuclear cells (PBMCs) and in gastric tumors. Multicolor flow cytometry analysis revealed that a subset of CD19+CD24hiCD38hi B cells produces IL-10. Functional studies indicated that increased Bregs do not inhibit the proliferation of CD3+T cells or CD4+ helper T cells (Th cells). However, Bregs do suppress the secretion of IFN-γ and TNF-α by CD4+Th cells. CD19+CD24hiCD38hiBregs were also found to correlate positively with CD4+FoxP3+ regulatory T cells (Tregs). Neutralization experiments showed that Bregs convert CD4+CD25- effector T cells to CD4+FoxP3+Tregs via TGF-β1. Collectively, these findings demonstrate that increased Bregs play a immunosuppressive role in gastric cancer by inhibiting T cells cytokines as well as conversion to Tregs. These results may provide new clues about the underlying mechanisms of immune escape in gastric cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5588